Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 3 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Gh Research Ireland Limited is currently overseeing 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 9 actions are distributed among 9 distinct examiners, resulting in a unique examiner for every pending matter. While the personnel are diverse, the applications are grouped into 3 distinct art units. This indicates that while many individuals are involved, the technical scope is relatively concentrated within a few specialized divisions at the patent office.
JACKSON, SHAWQUIA is the busiest examiner for this portfolio, with 1 pending office action. Given that there are 9 distinct examiners for 9 total actions, this single action is the maximum assigned to any individual. The use of 3 distinct art units for the 9 pending office actions indicates that the Biotechnology & Pharmaceuticals portfolio is concentrated in a few specific technical niches. This concentration suggests that multiple applications are being reviewed within the same specialized divisions, even though they are handled by different examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting + other | 5 (56%) |
| Multi-statute (no §101) | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18373903 | TREATMENT OF MENTAL DISORDERS | DEKARSKE, MADELINE MCGUIRE | 60d overdue |
| 18851346 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | COUGHLIN, MATTHEW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18373906 | TREATMENT OF MENTAL DISORDERS | BURKETT, DANIEL JOHN | 31d overdue |
| 18851346 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | COUGHLIN, MATTHEW P | — |
| 18851349 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | ROZOF, TIMOTHY R | — |
| 18851294 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF ANXIETY | WHITE, DAWANNA SHAR-DAY | — |
| 18850348 | TREATMENT OF ANXIETY | RODRIGUEZ, RAYNA B | — |
| 18850362 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION | SCHMIDT, IZABELA MARIA | — |
| 18675614 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING DEPRESSION | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1622 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920063 | ORGANIC COMPOUND SALTS | JACKSON, SHAWQUIA | — | §103DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18851346 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | COUGHLIN, MATTHEW P | — | §101§102§112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18851349 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | ROZOF, TIMOTHY R | — | §102DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18851294 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF ANXIETY | WHITE, DAWANNA SHAR-DAY | — | §102§103DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18850348 | TREATMENT OF ANXIETY | RODRIGUEZ, RAYNA B | — | §102§103DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18850362 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION | SCHMIDT, IZABELA MARIA | — | §102§103DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18675614 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING DEPRESSION | LEE, CHIHYI NMN | 1628 | §103Other | Final Rejection | — | Pending | May 28, 2024 |
| 18373903 | TREATMENT OF MENTAL DISORDERS | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103Other | Final Rejection | 60d overdue | Pending | Sep 27, 2023 |
| 18373906 | TREATMENT OF MENTAL DISORDERS | BURKETT, DANIEL JOHN | 1624 | §112 | Final Rejection | 31d overdue | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial